CNTX_OUT_1 [2025-03-25 15:44:30 -0400] 1919 Bytes | 523 tokens | Cum: 523 tkns (6.54% of 8k)
==========================================================================

Listen up, partner—it's 3:44:29 PM on Tue Mar 25, 2025 -0400, and I’m revved up about Context Therapeutics (CNTX), climbing from 0.764 to 0.9792. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

Here's the first list of news for Context Therapeutics:

C1 - Mar-20-25 04:22PM - Context Therapeutics Reports Full Year 2024 Operating and Financial Results
C2 - Feb-24-25 05:05PM - Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
C3 - Feb-19-25 07:30AM - Context Therapeutics to Participate in Upcoming Investor Conferences
C4 - Jan-15-25 11:29AM - Context doses first subject in Phase I cancer trial of CTIM-76
C5 - Jan-14-25 04:58PM - Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
C6 - Jan-13-25 07:30AM - Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
C7 - Dec-26-24 11:26AM - Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment
C8 - Nov-06-24 04:06PM - Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Context Therapeutics (CNTX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

CNTX_OUT_3 [2025-03-25 15:44:33 -0400] 1046 Bytes | 288 tokens | Cum: 813 tkns (10.16% of 8k)
==========================================================================

Showing C1 (chunk 1 of 7): C1:
**Context Therapeutics Reports Full Year 2024 Operating and Financial Results**
Date: Mar-20-25 04:22PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/20/3046728/0/en/Context-Therapeutics-Reports-Full-Year-2024-Operating-and-Financial-Results.html

March 20, 2025 16:22 ET| Source:Context Therapeutics Inc.Context Therapeutics Inc.

Cash and cash equivalents of $94.4 million as of December 31, 2024

Company expects its cash and cash equivalents will continue to fund operations into 2027

PHILADELPHIA, March 20, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2024, and reported on recent and upcoming business highlights.

Martin

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CNTX_OUT_5 [2025-03-25 15:44:35 -0400] 904 Bytes | 274 tokens | Cum: 1089 tkns (13.61% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-24T09:46:23Z - Citizens JMP Reiterates Market Outperform Rating on Context Therapeutics (CNTX)...
A2 - 2025-03-24T08:21:11Z - Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Rating of "Buy" from Analysts...
A3 - 2025-03-24T05:49:41Z - What is HC Wainwright's Forecast for CNTX Q3 Earnings?...
A4 - 2025-03-22T13:46:07Z - Context Therapeutics (NASDAQ:CNTX) Issues Quarterly Earnings Results...
A5 - 2025-03-22T12:32:46Z - Context Therapeutics (NASDAQ:CNTX) Earns "Buy" Rating from D. Boral Capital...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CNTX_OUT_7 [2025-03-25 15:44:37 -0400] 1038 Bytes | 288 tokens | Cum: 1379 tkns (17.24% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**Citizens JMP Reiterates Market Outperform Rating on Context Therapeutics (CNTX)**Date: 2025-03-24Source: {'uri': 'streetinsider.com', 'dataType': 'news', 'title': 'StreetInsider.com'}URL: https://www.streetinsider.com/Analyst+Comments/Citizens+JMP+Reiterates+Market+Outperform+Rating+on+Context+Therapeutics+%28CNTX%29/24536337.htmlCitizens JMP analyst Silvan Tuerkcan reiterated a Market Outperform rating and $4.00 price target on Context Therapeutics (NASDAQ: CNTX).

The analyst commented, "As Context Therapeutics moves its second asset into the clinic in 2Q25, the company issued full-year financial results. Context ended 2024 with $94.4M in cash and cash equivalents, and had FY opex of $29.9M, which is expected to fund operations through two interim clinical readouts and into 2027. We maintain our Market Outperform rating and $4 DCF-derived price target... CNTX is an early-stage co

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CNTX_OUT_9 [2025-03-25 15:44:38 -0400] 862 Bytes | 288 tokens | Cum: 1670 tkns (20.88% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-14T21:58:00Z - Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
B2 - 2024-12-26T16:26:00Z - Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment
B3 - 2024-12-20T20:45:00Z - Top 10 Small-Cap Stocks to Watch in 2025
B4 - 2024-06-12T13:40:09Z - Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year?
B5 - 2024-05-20T16:00:10Z - Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice
B6 - 2024-05-14T16:00:08Z - Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CNTX_OUT_11 [2025-03-25 15:44:42 -0400] 496 Bytes | 134 tokens | Cum: 1806 tkns (22.57% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**Top 10 Small-Cap Stocks to Watch in 2025**Date: Unknown DateSource: Unknown SourceURL: https://www.investing.com/analysis/top-10-smallcap-stocks-to-watch-in-2025-200655548The article discusses 10 small-cap stocks that could outperform in 2025, citing factors like falling interest rates, low valuations, and potential shifts in industrial production.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CNTX_OUT_13 [2025-03-25 15:44:44 -0400] 1131 Bytes | 286 tokens | Cum: 2160 tkns (27.00% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-20 10-K Item 7. Management's Discussion and Analysis of Fin Cond and Results of Oper

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other finan...

S6 - 2025-01-14 8-K Item 7.01. Regulation FD Disclosure.

On January 14, 2025, Context Therapeutics Inc. (the "Company") issued a press release announcing that the first patient has been dosed in the Companys Phase 1 clinical trial evaluating CTIM-76. A copy of the press release is attached as Exhi...

S9 - 2025-01-13 8-K Item 7.01. Regulation FD Disclosure.

On January 13, 2025, the Company issued a press release announcing the appointment of Mr. Pasternak to the Board. A copy of the press release is attached as Exhibit 99.1 to this Curr Report on Form 8-K and is incorporated herein by refere...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CNTX_OUT_15 [2025-03-25 15:44:45 -0400] 1038 Bytes | 201 tokens | Cum: 2363 tkns (29.54% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this Form 10-K. Some of the information contained in this discussion and analysis, including information with respect to our plans and strategy for our business, contains forward-looking statements that involve risks and uncertainties. You should review the section titled Risk Factors in this Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described below. Please also see the section entitled Note Regarding Forward-Looking Statements.

Overview

We are a clinical-stage biopharmaceutical company advanc

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CNTX_OUT_17 [2025-03-25 15:44:47 -0400] 1038 Bytes | 281 tokens | Cum: 2646 tkns (33.07% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): ing TCE bispecific antibodies for solid tumors. We are building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a CLDN6 x CD3 TCE, CT-95, an MSLN x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE.

CTIM-76 is a CLDN6 x CD3 TCE that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. IND-enabling studies on CTIM-76 have been completed. On May 2, 2024, we announced the FDA cleared our IND application to support the initiation of a Phase 1 dose escalation and expansion trial of CTIM-76 in patients with CLDN6-positive gynecologic and testicular cancers. We dosed the first patient in our CTIM-76 Phase 1 trial in January 2025. We expect to share initial data for the CTIM-76 Phase 1 tria

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CNTX_OUT_19 [2025-03-25 15:44:52 -0400] 1038 Bytes | 258 tokens | Cum: 2906 tkns (36.33% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): l in the first half of 2026.

On September 23, 2024, we entered into the BioAtla License Agreement with BioAtla, pursuant to which we obtained an exclusive, worldwide license to develop, manufacture and commercialize the BioAtla Asset, including BA3362 (renamed by the Company as CT-202), BioAtlas Nectin-4 x CD3 TCE.

As partial consideration for the exclusive license under the BioAtla License Agreement, we made an upfront payment of $11.0 million, and BioAtla is eligible to receive up to $122.5 million in additional milestone payments based upon the achievement of specified pre-clinical, clinical, development and commercial milestones, as well as tiered mid-single digit to low double-digit royalties on future net sales for products containing the BioAtla Assets, subject to standard reductions.

CT-202 is a Nectin-4 x CD3 TCE that targets Nectin-4, a cell surface protein that is highly

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CNTX_OUT_21 [2025-03-25 15:44:58 -0400] 1038 Bytes | 246 tokens | Cum: 3283 tkns (41.04% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): and frequently overexpressed in a variety of solid tumors, including bladder, colorectal, lung and breast. Nectin-4 is a clinically validated target for cancer therapy using a traditional antibody-drug conjugate (ADC), but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the tumor microenvironment. We expect to file an IND application for CT-202 in the middle of 2026.

On July 9, 2024, we entered into the Asset Purchase Agreement pursuant to which we acquired CT-95 (formerly known as LNK-101), from Link, which succeeded to the assets of Link Immunotherapeutics Inc. The FDA previously cleared the IND application for CT-95.

Pursuant to the Asset Purchase Agreement, we purchased the Transferred Assets on an as is and where is basis. CT-95 patents are currently being prosecut

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CNTX_OUT_23 [2025-03-25 15:45:04 -0400] 1038 Bytes | 260 tokens | Cum: 3688 tkns (46.10% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): ed and/or maintained in the United States, Europe, Canada, Australia, Japan and Taiwan. We also assumed certain liabilities relating to the Transferred Assets. In consideration of the Transferred Assets, we made a one-time payment to Link of $3.75 million.

CT-95 is an MSLN x CD3 TCE that is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. We anticipate dosing the first patient in the CT-95 Phase 1 trial in the second quarter of 2025. We expect to share initial data for the CT-95 Phase 1 trial in the middle of 2026.

On December 2, 2024, we entered into the ATM Sales Agreement with Agent. Pursuant to the terms of the ATM Sales Agreement, we may offer and sell ATM Shares having an aggregate offering amount of up to $75.0

Table of Contents

million from time to time through the

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CNTX_OUT_25 [2025-03-25 15:45:10 -0400] 647 Bytes | 168 tokens | Cum: 3942 tkns (49.28% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): Agent. Sales of the ATM Shares may be made in sales deemed to be an at-the-market offering as defined in Rule 415 under the Securities Act. The Agent will be entitled to a commission from the Company of 3.0% of the gross proceeds from the sale of ATM Shares sold under the ATM Sales Agreement. On December 23, 2024, the Company sold 14,705,882 shares of its common stock under the ATM Sales Agreement for net proceeds of approximately $14.5 million.

On May 1, 2024, we entered into the Purchase Agreeme...

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

CNTX_OUT_27 [2025-03-25 15:45:24 -0400] 5034 Bytes | 1424 tokens | Cum: 5457 tkns (68.21% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+----------------------+------------------------+----------------------+----------------------+
| Volume: 96,561 | SMA50: 6.50% | Market Cap: 67.87M | Option/Short: No / Yes | Sales past 5Y: 0.00% | Sales Surprise: - |
+---------------------+-----------------------+----------------------+------------------------+----------------------+----------------------+
| Avg Volume: 188.55K | SMA200: -45.85% | Shs Outstand: 89.70M | Short Float: 5.65% | Employees: 12 | EPS Surprise: 67.39% |
+---------------------+-----------------------+----------------------+------------------------+----------------------+----------------------+
| Rel Volume: 0.56 | Perf Week: 13.82% | Shs Float: 43.75M | Short Ratio: 13.11 | Debt/Eq: 0.00 | P/E: - |
+---------------------+-----------------------+----------------------+------------------------+----------------------+----------------------+
| RSI (14): 57.80 | Perf Month: 8.84% | Inst Own: 56.83% | Short Interest: 2.47M | Sales Y/Y TTM: - | Earnings: Mar 20 AMC |
+---------------------+-----------------------+----------------------+------------------------+----------------------+----------------------+
| ATR (14): 0.09 | Perf Quarter: -16.98% | Insider Own: 41.67% | Beta: 2.08 | ROE: -49.89% | |
+---------------------+-----------------------+----------------------+------------------------+----------------------+----------------------+
| SMA20: 13.99% | Index: - | Insider Trans: 0.00% | Sales Q/Q: - | ROI: -28.02% | |
+---------------------+-----------------------+----------------------+------------------------+----------------------+----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Context Therapeutics Inc. (CNTX) by Lehr Martin A. (Chief Executive Officer) on 2025-02-13
- Stock Option (right to buy): 802700 shares at $0 (D)

Inside Trans: Context Therapeutics Inc. (CNTX) by Dansky Ullmann Claudio (Chief Medical Officer) on 2025-02-13
- Stock Option (right to buy): 174960 shares at $0 (D)

Inside Trans: Context Therapeutics Inc. (CNTX) by Levit Alex C. (Chief Legal Officer, Corp. Sec) on 2025-02-13
- Stock Option (right to buy): 349900 shares at $0 (D)

Inside Trans: Context Therapeutics Inc. (CNTX) by Minai-Azary Jennifer Lynn (Chief Financial Officer) on 2025-02-13
- Stock Option (right to buy): 371800 shares at $0 (D)

No transactions recorded.

Inside Trans: Context Therapeutics Inc. (CNTX) by Pasternak Andy (Unknown Title) on 2025-01-13
- Stock Option (right to buy): 20685 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: Context Therapeutics Inc. Common Stock
Market Cap: N/A
Shares Outstanding: N/A
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: {'value': -26725104.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.9606
Average Volume: 68832.45
30-Day High: 0.9606
30-Day Low: 0.6536

[Detailed Financials: TTM 2024]
- Total Assets: $98,126,759.0
- Total Liabilities: $2,860,497.0
- Total Equity: $95,266,262.0
- Current Assets: $97,895,984.0
- Current Liabilities: $2,748,433.0

[Income Statement: TTM 2024]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.46

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $79,979,997.0

[Detailed Financials: FY 2024]
- Total Assets: $98,126,759.0
- Total Liabilities: $2,860,497.0
- Total Equity: $95,266,262.0
- Current Assets: $97,895,984.0
- Current Liabilities: $2,748,433.0

[Income Statement: FY 2024]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.46

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $79,979,997.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

CNTX_OUT_29 [2025-03-25 15:45:27 -0400] 676 Bytes | 167 tokens | Cum: 5894 tkns (73.67% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

CNTX_IN_31 [2025-03-25 15:45:27 -0400] 126 Bytes | 29 tokens | Cum: 5951 tkns (74.39% of 8k)
==========================================================================

====================================
[2025-03-25 12:45:27] # Analysis Completed
Elapsed Time: 59.73 seconds